title: Glycaemic efficacy of canagliflozin is largely independent of baseline β-cell function or insulin sensitivity.
authors.affiliation: University of Oxford, Oxford, UK.
authors.forename: D R
authors.initials: DR
authors.lastname: Matthews
authors.affiliation: Luenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
authors.forename: B
authors.initials: B
authors.lastname: Zinman
authors.affiliation: Janssen Research & Development, LLC, Raritan, NJ, USA.
authors.forename: C
authors.initials: C
authors.lastname: Tong
authors.affiliation: Janssen Research & Development, LLC, Raritan, NJ, USA.
authors.forename: G
authors.initials: G
authors.lastname: Meininger
authors.affiliation: Janssen Research & Development, LLC, San Diego, CA, USA.
authors.forename: D
authors.initials: D
authors.lastname: Polidori
mesh_terms: D001786:Blood Glucose / Q000187:drug effects* / Q000378:metabolism; D000068896:Canagliflozin / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic / Q000706:statistics & numerical data; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000453:epidemiology / Q000378:metabolism / Q000503:physiopathology; D004311:Double-Blind Method; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance; D050417:Insulin-Secreting Cells / Q000187:drug effects* / Q000502:physiology; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D000068896:Canagliflozin; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; C517652:hemoglobin A1c protein, human